Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
petunidin
- Development stage
- Preclinical
- Lead developer
- University of Quebec in Montreal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Petunidin is an O-methylated anthocyanidin, a natural plant pigment found in various berries, red grapes, and other pigmented plants. It belongs to the class of flavonoids and is known for its antioxidant and anti-inflammatory properties. In oncological research, petunidin has been investigated for its ability to inhibit the epithelial-mesenchymal transition (EMT) induced by Transforming Growth Factor-beta (TGF-β) in glioblastoma multiforme (GBM) cells. Its mechanism of action involves the down-regulation of mesenchymal markers such as fibronectin and snail, as well as the inhibition of Smad2 phosphorylation and mitogen-activated protein kinase (MAPK) signaling pathways, including ERK and JNK. While petunidin demonstrates potential anti-metastatic and chemopreventive effects in preclinical models, it is primarily recognized as a dietary polyphenol and nutraceutical rather than a clinical-stage pharmaceutical drug.
- Other names
- petunidin chloride3,3',4',5,7-pentahydroxy-5'-methoxyflavylium
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)SMAD2 (Mothers against decapentaplegic homolog 2)SNAI1 (Snail family transcriptional repressor 1)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on petunidin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on petunidin.